新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

300519 新光药业

已收盘 12-23 15:00:00

{"stockData":{"symbol":"300519","market":"SZ","secType":"STK","nameCN":"新光药业","latestPrice":15.36,"timestamp":1766473416000,"preClose":15.45,"halted":0,"volume":2172700,"delay":0,"changeRate":-0.0058,"floatShares":113999999,"shares":160000000,"eps":0.3622,"marketStatus":"已收盘","change":-0.09,"latestTime":"12-23 15:00:00","open":15.47,"high":15.48,"low":15.24,"amount":33284200,"amplitude":0.0155,"askPrice":15.37,"askSize":39,"bidPrice":15.36,"bidSize":71,"shortable":0,"etf":0,"ttmEps":0.3622,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766539800000},"marketStatusCode":5,"adr":0,"adjPreClose":15.45,"symbolType":"stock","openAndCloseTimeList":[[1766453400000,1766460600000],[1766466000000,1766473200000]],"highLimit":17,"lowLimit":13.91,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":160000000,"isCdr":false,"pbRate":2.99,"roa":"--","peRate":42.40751,"roe":"5.45%","epsLYR":0.31,"committee":-0.14053,"marketValue":2458000000,"turnoverRate":0.019,"status":1,"floatMarketCap":1753000000},"requestUrl":"/m/hq/s/300519/tweets","defaultTab":"tweets","newsList":[{"id":"2590595960","title":"新光药业：新药“YHTKL”进入工艺及质量标准研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2590595960","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590595960?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:31","pubTimestamp":1765441878,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)12月11日在投资者关系平台上答复投资者关心的问题。投资者提问：贵公司的创新药研究的怎么样了？新光药业回复：您好，感谢您对本公司的关注。公司定期报告披露的新药“YHTKL”目前已完成处方的基础研究，现已进入工艺及质量标准的研究阶段。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100023799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0239","BK0132"],"gpt_icon":0},{"id":"2589850942","title":"新光药业：产品无外销不包括境外地区","url":"https://stock-news.laohu8.com/highlight/detail?id=2589850942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589850942?lang=zh_cn&edition=full","pubTime":"2025-12-05 11:37","pubTimestamp":1764905865,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)12月05日在投资者关系平台上答复投资者关心的问题。投资者提问：您好，看到贵司23、24年财报披露中，有部分营业收入来自“浙江省以外地区”，请问此收入来源地区是否包含境外的国家/地区？如有，是否包含欧盟地区的国家呢？新光药业回复：您好，感谢您对本公司的关注。本公司产品无外销，该部分营业收入不包括境外国家和地区。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120500013535.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","300519"],"gpt_icon":0},{"id":"1101660455","title":"新光药业股东计划减持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1101660455","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101660455?lang=zh_cn&edition=full","pubTime":"2025-11-20 00:58","pubTimestamp":1763571510,"startTime":"0","endTime":"0","summary":"11月6日 - 新光药业股份有限公司 <300519.SZ>::*公告称，股东计划减持高达3%的公司股份","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0132","BK0239","300519"],"gpt_icon":0},{"id":"2581064391","title":"新光药业最新公告：股东和丰投资拟减持不超3%公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2581064391","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581064391?lang=zh_cn&edition=full","pubTime":"2025-11-06 19:49","pubTimestamp":1762429797,"startTime":"0","endTime":"0","summary":"新光药业(300519.SZ)公告称，持股5%以上股东嵊州市和丰投资股份有限公司计划减持不超过480万股（占公司总股本的3%），其中通过集中竞价交易方式减持不超过160万股（不超过总股本的1%），通过大宗交易方式减持不超过320万股（不超过总股本的2%）。减持原因为股东个人资金安排需求，减持期间为公告披露之日起15个交易日后的3个月内（2025年11月28日至2026年2月27日）。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110600034218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"gpt_icon":0},{"id":"2578617091","title":"图解新光药业三季报：第三季度单季净利润同比增长9.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578617091","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578617091?lang=zh_cn&edition=full","pubTime":"2025-10-27 18:54","pubTimestamp":1761562447,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业2025年三季报显示，公司主营收入2.06亿元，同比下降4.9%；归母净利润4533.62万元，同比上升19.99%；扣非净利润4348.86万元，同比上升25.86%；其中2025年第三季度，公司单季度主营收入6467.56万元，同比下降7.61%；单季度归母净利润1342.85万元，同比上升9.4%；单季度扣非净利润1404.94万元，同比上升17.28%；负债率7.33%，投资收益292.76万元，财务费用-1103.07万元，毛利率39.12%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700029253.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"gpt_icon":0},{"id":"2578657032","title":"股市必读：新光药业（300519）10月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2578657032","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578657032?lang=zh_cn&edition=full","pubTime":"2025-10-27 05:18","pubTimestamp":1761513494,"startTime":"0","endTime":"0","summary":"截至2025年10月24日收盘，新光药业报收于16.37元，上涨0.43%，换手率2.38%，成交量2.72万手，成交额4444.45万元。本公司主要从事中成药、化学药、保健食品的研发、生产和销售。截止目前，公司暂不涉及生物药的研发与生产。当日关注点来自交易信息汇总：10月24日主力资金净流出282.87万元，散户资金净流入400.23万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700001455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"gpt_icon":0},{"id":"2577556011","title":"新光药业：暂不涉及生物药研发与生产","url":"https://stock-news.laohu8.com/highlight/detail?id=2577556011","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577556011?lang=zh_cn&edition=full","pubTime":"2025-10-24 15:33","pubTimestamp":1761291190,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业10月24日在投资者关系平台上答复投资者关心的问题。投资者提问：我是投资者，特向贵司咨询以下问题，恳请予以说明1.贵公司目前在研的 生物药项目，目前分别处于临床的哪个阶段？本公司主要从事中成药、化学药、保健食品的研发、生产和销售。截止目前，公司暂不涉及生物药的研发与生产。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102400022480.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300519","159839","BK0132"],"gpt_icon":0},{"id":"2568233494","title":"9月17日新光药业发布公告，股东减持36.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2568233494","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568233494?lang=zh_cn&edition=full","pubTime":"2025-09-17 22:01","pubTimestamp":1758117695,"startTime":"0","endTime":"0","summary":"证券之星消息，9月17日新光药业发布公告《新光药业:关于公司持股5%以上股东股份减持计划届满的公告》，其股东嵊州市和丰投资股份有限公司于2025年9月16日合计减持36.1万股，占公司目前总股本的0.2256%，变动期间该股股价上涨0.61%，截止9月16日收盘报16.54元。股东增减持详情见下表：根据新光药业2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091700040126.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0239","BK0132"],"gpt_icon":0},{"id":"2567102109","title":"9月16日新光药业发布公告，股东减持123.89万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2567102109","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567102109?lang=zh_cn&edition=full","pubTime":"2025-09-16 20:01","pubTimestamp":1758024102,"startTime":"0","endTime":"0","summary":"证券之星消息，9月16日新光药业发布公告《新光药业:关于公司持股5%以上股东减持股份触及1%整倍数的公告》，其股东嵊州市和丰投资股份有限公司于2025年7月31日至2025年9月15日间合计减持123.89万股，占公司目前总股本的0.7743%，变动期间该股股价下跌0.96%，截止9月15日收盘报16.44元。股东增减持详情见下表：根据新光药业2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091600034258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300519","BK0239"],"gpt_icon":0},{"id":"2562763194","title":"新光药业（300519）2025年中报简析：净利润同比增长25.09%，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2562763194","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562763194?lang=zh_cn&edition=full","pubTime":"2025-08-27 06:28","pubTimestamp":1756247302,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期新光药业发布2025年中报。截至本报告期末，公司营业总收入1.41亿元，同比下降3.6%，归母净利润3190.77万元，同比上升25.09%。本报告期新光药业盈利能力上升，毛利率同比增幅7.64%，净利率同比增幅29.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082700008865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519"],"gpt_icon":0},{"id":"2562381221","title":"新光药业股价微涨0.41% 上半年净利润同比增长25.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562381221","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562381221?lang=zh_cn&edition=full","pubTime":"2025-08-26 01:31","pubTimestamp":1756143070,"startTime":"0","endTime":"0","summary":"新光药业最新股价报17.10元，较前一交易日上涨0.41%。盘中最高触及17.23元，最低下探至16.96元，成交量为48923手，成交金额达0.84亿元。新光药业属于中药行业，公司主要从事中成药、化学药、保健食品的研发、生产和销售。公司8月25日披露的半年报显示，上半年实现营业收入1.41亿元，归属于上市公司股东的净利润3190.77万元，同比增长25.09%。基本每股收益为0.2元。从资金流向来看，8月25日主力资金净流出947.32万元，近五日主力资金累计净流出7487.12万元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26013152680050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300519"],"gpt_icon":0},{"id":"2561186418","title":"股市必读：新光药业（300519）8月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2561186418","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561186418?lang=zh_cn&edition=full","pubTime":"2025-08-22 02:20","pubTimestamp":1755800424,"startTime":"0","endTime":"0","summary":"截至2025年8月21日收盘，新光药业报收于17.16元，下跌1.15%，换手率5.28%，成交量6.03万手，成交额1.04亿元。董秘最新回复投资者： 董秘你好，公司主营业务是中成药，化学药，保健食品的研发，生产和销售。交易信息汇总8月21日，新光药业的资金流向显示主力资金净流出2624.77万元；游资资金净流入970.08万元；散户资金净流入1654.69万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082200002059.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0239","BK0132"],"gpt_icon":0},{"id":"2556809512","title":"新光药业：公司治疗肝病方面的药物主要有护肝片、金胆片、四季菜颗粒等","url":"https://stock-news.laohu8.com/highlight/detail?id=2556809512","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556809512?lang=zh_cn&edition=full","pubTime":"2025-08-04 16:18","pubTimestamp":1754295505,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司治疗肝炎的药物有哪些 有没有研发新药新光药业回复：您好，感谢您对本公司的关注。公司治疗肝病方面的药物主要有：护肝片、金胆片、四季菜颗粒等。暂未涉及这方面的新药研发。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080400021205.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0132","BK0239"],"gpt_icon":0},{"id":"2556809918","title":"新光药业：重点围绕新产品创新研发以及中药的二次开发","url":"https://stock-news.laohu8.com/highlight/detail?id=2556809918","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556809918?lang=zh_cn&edition=full","pubTime":"2025-08-04 16:18","pubTimestamp":1754295502,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵公司对中药后期研发有哪些布局 对创新药研发有什么进展新光药业回复：您好，感谢您对本公司的关注！公司在产品研发方面，重点围绕新产品创新研发以及中药的二次开发，致力于制备工艺的优化改进以及产品质量标准的提升研究。以不断丰富产品管线，拓展产品适应症，提升企业核心竞争力。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025080400021185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"gpt_icon":0},{"id":"2555600074","title":"新光药业：合作开发新药YHTKL进入工艺研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2555600074","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555600074?lang=zh_cn&edition=full","pubTime":"2025-07-31 16:54","pubTimestamp":1753952081,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)07月31日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，贵公司有什研发中的创新药吗？新光药业回复：您好，感谢您对本公司的关注。如年报披露，报告期内，公司合作开发的新药经典名方“YHTKL”目前已进入工艺研究阶段。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025073100026593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0239","300519"],"gpt_icon":0},{"id":"2548611268","title":"新光药业：本公司全国独家品种无糖型增液颗粒常年生产正常销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2548611268","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548611268?lang=zh_cn&edition=full","pubTime":"2025-07-02 16:42","pubTimestamp":1751445732,"startTime":"0","endTime":"0","summary":"证券之星消息，新光药业(300519)07月02日在投资者关系平台上答复投资者关心的问题。投资者提问：请问一下贵公司的产品增液颗粒在市场上没有销售，不知道为什么？是原材料涨价还是什么原因。不知何时可以恢复生产销售？新光药业回复：您好，感谢您对本公司的关注。本公司全国独家品种无糖型增液颗粒常年生产，正常销售。您或贵公司有需要，可与公司销售部门联系，联系电话：0575-83292166。谢谢。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070200026406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300519","BK0239","BK0132"],"gpt_icon":0},{"id":"2514069949","title":"新光药业收盘下跌1.54%，滚动市盈率49.32倍，总市值21.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514069949","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514069949?lang=zh_cn&edition=full","pubTime":"2025-02-25 18:11","pubTimestamp":1740478305,"startTime":"0","endTime":"0","summary":"2月25日，新光药业今日收盘13.39元，下跌1.54%，滚动市盈率PE达到49.32倍，总市值21.42亿元。从行业市盈率排名来看，公司所处的中药行业市盈率平均38.11倍，行业中值24.67倍，新光药业排名第54位。资金流向方面，2月25日，新光药业主力资金净流出415.71万元，近5日总体呈流出状态，5日共流出797.07万元。最新一期业绩显示，2024年三季报，公司实现营业收入2.16亿元，同比0.05%；净利润3778.24万元，同比-35.63%，销售毛利率35.08%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/02/25181148375901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK0132","300519","BK0239"],"gpt_icon":0},{"id":"2501874932","title":"1月8日新光药业发布公告，其股东减持144.6万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2501874932","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501874932?lang=zh_cn&edition=full","pubTime":"2025-01-08 18:01","pubTimestamp":1736330489,"startTime":"0","endTime":"0","summary":"证券之星消息，1月8日新光药业发布公告《新光药业:关于持股5%以上股东减持股份比例达到1%的公告》，其股东嵊州市和丰投资股份有限公司于2024年4月9日至2025年1月6日间合计减持144.6万股，占公司目前总股本的0.9038%，变动期间该股股价上涨10.63%，截止1月6日收盘报13.22元。股东增减持详情见下表：根据新光药业2024年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010800032168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300519","BK0132"],"gpt_icon":0},{"id":"2501216225","title":"新光药业（300519）1月7日主力资金净卖出405.80万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501216225","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501216225?lang=zh_cn&edition=full","pubTime":"2025-01-07 15:27","pubTimestamp":1736234838,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2025年1月7日收盘，新光药业报收于12.97元，下跌1.89%，换手率2.94%，成交量3.36万手，成交额4322.4万元。1月7日的资金流向数据方面，主力资金净流出405.8万元，占总成交额9.39%，游资资金净流入54.78万元，占总成交额1.27%，散户资金净流入351.02万元，占总成交额8.12%。新光药业主营业务：主要从事中成药、化学药、保健食品的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025010700020669.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","300519","BK0239"],"gpt_icon":0},{"id":"2501288452","title":"新光药业1月6日现5笔大宗交易 成交金额1194.81万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2501288452","media":"新浪证券-红岸工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501288452?lang=zh_cn&edition=full","pubTime":"2025-01-06 17:00","pubTimestamp":1736154000,"startTime":"0","endTime":"0","summary":"　　1月6日，新光药业收涨5.93%，收盘价为13.22元，发生5笔大宗交易，合计成交量119.6万股，成交金额1194.81万元。　　第2笔成交价格为9.99元，成交26.50万股，成交金额264.74万元，溢价率为-24.43%，买方营业部为海通证券股份有限公司嵊州高杨路证券营业部，卖方营业部为海通证券股份有限公司嵊州高杨路证券营业部。　　进一步统计，近3个月内该股累计发生6笔大宗交易，合计成交金额为1470.81万元。该股近5个交易日累计下跌4.41%，主力资金合计净流入12.08万元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2025-01-06/doc-inecznxv3067159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["300519","BK0132","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1766480877782,"stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0144},{"period":"3month","weight":-0.0006},{"period":"6month","weight":0.0604},{"period":"1year","weight":0.073},{"period":"ytd","weight":0.1886}],"compareEarnings":[{"period":"1week","weight":0.0128},{"period":"1month","weight":0.0215},{"period":"3month","weight":0.025},{"period":"6month","weight":0.1335},{"period":"1year","weight":0.1631},{"period":"ytd","weight":0.1687}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江新光药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15602人(较上一季度增加10.29%)","perCapita":"7313股","listingDate":"2016-06-24","address":"浙江省绍兴市嵊州市剡湖街道环城西路25号","registeredCapital":"16000万元","survey":"　　浙江新光药业股份有限公司的主营业务是中成药、化学药、保健食品的研发、生产和销售。公司的主要产品是黄芪生脉饮、伸筋丹胶囊、西洋参口服液、黄芪生脉颗粒、增液颗粒、慢支固本颗粒。公司主导产品黄芪生脉饮多次获得“浙江省名牌产品”称号和“中国中药名牌产品”称号，为公司赢得了良好的品牌形象。“新光”商标多次荣获“浙江省著名商标”称号。黄芪生脉饮入选浙江省首批“浙产名药”。公司拥有核心自主知识产权11项，其中以自主研发方式获得的发明专利6项。","listedPrice":12.2},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供新光药业(300519)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"新光药业,300519,新光药业股票,新光药业股票老虎,新光药业股票老虎国际,新光药业行情,新光药业股票行情,新光药业股价,新光药业股市,新光药业股票价格,新光药业股票交易,新光药业股票购买,新光药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"新光药业(300519)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供新光药业(300519)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}